Cytobioteck to distribute Pharming’s Ruconest

26 May 2015

Netherlands-based Pharming Group (Euronext: PHARM) has entered into an exclusive distribution agreement with Cytobioteck, a privately owned Bogota, Colombia-based specialty health care company, for the distribution of Ruconest (recombinant human C1 inhibitor) for the treatment of acute attacks of hereditary angioedema (HAE) in Colombia and Venezuela.

Under the agreement, Cytobioteck will drive all regulatory processes and will purchase its commercial supplies of Ruconest from Pharming at a fixed transfer price. No further terms of the accord were disclosed.

Sijmen de Vries, Pharming’s chief executive, commented: “we are very pleased that Cytobioteck will be engaged in the distribution of Ruconest in Colombia and Venezuela, two countries where a considerable number of patients with HAE have been diagnosed.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology